Disc Medicine Valuation
| IRON Stock | 64.00 2.64 4.30% |
At this time, the firm appears to be undervalued. Disc Medicine shows a prevailing Real Value of USD81.0 per share. The current price of the firm is USD64.0. Our model computes the value of Disc Medicine from reviewing the firm fundamentals such as Shares Owned By Insiders of 8.36 %, current valuation of 1.67 B, and Price To Book of 3.73 X as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Disc Medicine's valuation include:
Undervalued
Today
Please note that Disc Medicine's price fluctuation is very steady at this time. Calculation of the real value of Disc Medicine is based on 3 months time horizon. Increasing Disc Medicine's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Disc Medicine is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Disc Stock. However, Disc Medicine's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 64.0 | Real 81.0 | Target 103.42 | Hype 64.87 | Naive 56.8 |
The intrinsic value of Disc Medicine's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Disc Medicine's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Disc Medicine helps investors to forecast how Disc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Disc Medicine more accurately as focusing exclusively on Disc Medicine's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Disc Medicine's intrinsic value based on its ongoing forecasts of Disc Medicine's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Disc Medicine's closest peers.
Disc Medicine Cash |
|
Disc Medicine Total Value Analysis
Disc Medicine is currently estimated to have valuation of 1.67 B with market capitalization of 2.32 B, debt of 30 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Disc Medicine fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.67 B | 2.32 B | 30 M |
Disc Medicine Asset Utilization
One of the ways to look at asset utilization of Disc is to check how much profit was generated for every dollar of assets it reports. Disc Medicine shows a negative utilization of assets of -0.23 percent, losing USD0.002261 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Disc Medicine shows how discouraging it operates for each dollar spent on its assets.Disc Medicine Profitability Analysis
Based on the measurements of profitability obtained from Disc Medicine's financial statements, Disc Medicine may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Disc Medicine's ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -55.2 M | Current Value -62.3 M | Quarterly Volatility 15 M |
For Disc Medicine profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Disc Medicine to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Disc Medicine utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Disc Medicine's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Disc Medicine over time as well as its relative position and ranking within its peers.
Disc Medicine Earnings per Share Projection vs Actual
The next projected EPS of Disc Medicine is estimated to be -1.775625 with future projections ranging from a low of -2.485 to a high of -1.2975. Disc Medicine's most recent 12-month trailing earnings per share (EPS TTM) is at -5.37. Please be aware that the consensus of earnings estimates for Disc Medicine is based on EPS before non-recurring items and includes expenses related to employee stock options.Disc Medicine Earnings Estimation Breakdown
The calculation of Disc Medicine's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Disc Medicine is estimated to be -1.775625 with the future projection ranging from a low of -2.485 to a high of -1.2975. Please be aware that this consensus of annual earnings estimates for Disc Medicine is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.48 Lowest | Expected EPS | -1.3 Highest |
Disc Medicine Earnings Projection Consensus
Suppose the current estimates of Disc Medicine's value are higher than the current market price of the Disc Medicine stock. In this case, investors may conclude that Disc Medicine is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Disc Medicine's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 13 | 75.28% | 0.0 | -1.775625 | -5.37 |
Disc Medicine Ownership Allocation
The majority of Disc Medicine outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Disc Medicine to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Disc Medicine. Please pay attention to any change in the institutional holdings of Disc Medicine as this could imply that something significant has changed or is about to change at the company.Disc Medicine Profitability Analysis
Net Loss for the year was (109.36 M) with profit before overhead, payroll, taxes, and interest of 0.About Disc Medicine Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Disc Medicine. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Disc Medicine based exclusively on its fundamental and basic technical indicators. By analyzing Disc Medicine's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Disc Medicine's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Disc Medicine. We calculate exposure to Disc Medicine's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Disc Medicine's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -179.4 K | -188.4 K |
Disc Medicine Current Valuation Indicators
Disc Medicine's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Disc Medicine's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Disc Medicine, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Disc Medicine's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Disc Medicine's worth.When determining whether Disc Medicine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Disc Medicine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Disc Medicine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Disc Medicine Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Will Biotechnology sector continue expanding? Could Disc diversify its offerings? Factors like these will boost the valuation of Disc Medicine. Market participants price Disc higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Disc Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Disc Medicine using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Disc Medicine's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Disc Medicine's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Disc Medicine's market price signifies the transaction level at which participants voluntarily complete trades.